Shares of Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) shot up 0.6% during trading on Thursday . The stock traded as high as C$1.91 and last traded at C$1.70. 102,231 shares were traded during trading, a decline of 5% from the average session volume of 107,412 shares. The stock had previously closed at C$1.69.
Medicenna Therapeutics Stock Down 14.7 %
The stock’s 50-day moving average is C$2.14 and its 200-day moving average is C$2.18. The company has a current ratio of 2.51, a quick ratio of 4.65 and a debt-to-equity ratio of 0.06. The company has a market cap of C$110.82 million, a price-to-earnings ratio of -3.82 and a beta of 1.21.
About Medicenna Therapeutics
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
Recommended Stories
- Five stocks we like better than Medicenna Therapeutics
- Health Care Stocks Explained: Why You Might Want to Invest
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- How to buy stock: A step-by-step guide for beginners
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Time to Load Up on Home Builders?
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
